Russell Investments Group, Ltd. Ultragenyx Pharmaceutical Inc. Transaction History

Russell Investments Group, Ltd.

  • $66.8 Billion
  • Q3 2024

A detailed history of Russell Investments Group, Ltd. transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 88,611 shares of RARE stock, worth $3.88 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
88,611
Previous 156,053 43.22%
Holding current value
$3.88 Million
Previous $6.41 Million 23.25%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
SELL
$40.21 - $59.36 $2.71 Million - $4 Million
-67,442 Reduced 43.22%
88,611 $4.92 Million
Q2 2024

Aug 08, 2024
SELL
$37.42 - $51.61 $265,232 - $365,811
-7,088 Reduced 4.34%
156,053 $6.41 Million
Q1 2024

May 08, 2024
SELL
$43.02 - $53.69 $1.61 Million - $2.01 Million
-37,474 Reduced 18.68%
163,141 $7.62 Million
Q4 2023

Feb 05, 2024
BUY
$31.73 - $49.19 $530,779 - $822,850
16,728 Added 9.1%
200,615 $9.59 Million
Q3 2023

Nov 13, 2023
BUY
$34.92 - $46.66 $480,150 - $641,575
13,750 Added 8.08%
183,887 $6.56 Million
Q2 2023

Aug 10, 2023
SELL
$37.35 - $52.15 $451,935 - $631,015
-12,100 Reduced 6.64%
170,137 $7.85 Million
Q1 2023

May 09, 2023
BUY
$36.99 - $48.71 $2.69 Million - $3.54 Million
72,595 Added 66.21%
182,237 $7.31 Million
Q4 2022

Feb 08, 2023
BUY
$33.72 - $46.33 $548,523 - $753,650
16,267 Added 17.42%
109,642 $5.08 Million
Q3 2022

Nov 04, 2022
BUY
$39.96 - $66.14 $3.73 Million - $6.18 Million
93,375 New
93,375 $3.86 Million
Q2 2022

Jul 29, 2022
SELL
$45.8 - $85.4 $153,201 - $285,663
-3,345 Closed
0 $0
Q1 2022

May 05, 2022
BUY
$62.2 - $84.4 $208,059 - $282,318
3,345 New
3,345 $242,000
Q4 2021

Jan 21, 2022
SELL
$73.71 - $87.86 $184,422 - $219,825
-2,502 Closed
0 $0
Q3 2021

Nov 08, 2021
SELL
$77.92 - $102.4 $1.25 Million - $1.65 Million
-16,106 Reduced 86.55%
2,502 $225,000
Q2 2021

Aug 04, 2021
SELL
$92.19 - $115.71 $1.24 Million - $1.56 Million
-13,446 Reduced 41.95%
18,608 $1.77 Million
Q1 2021

May 10, 2021
SELL
$106.9 - $167.73 $798,115 - $1.25 Million
-7,466 Reduced 18.89%
32,054 $3.65 Million
Q4 2020

Feb 08, 2021
SELL
$84.4 - $177.39 $98,326 - $206,659
-1,165 Reduced 2.86%
39,520 $5.47 Million
Q3 2020

Nov 09, 2020
BUY
$72.98 - $90.0 $495,607 - $611,190
6,791 Added 20.04%
40,685 $3.34 Million
Q2 2020

Aug 05, 2020
SELL
$46.91 - $78.22 $684,557 - $1.14 Million
-14,593 Reduced 30.1%
33,894 $2.65 Million
Q1 2020

May 06, 2020
SELL
$33.8 - $62.9 $457,753 - $851,854
-13,543 Reduced 21.83%
48,487 $2.15 Million
Q4 2019

Jan 29, 2020
BUY
$36.08 - $45.83 $794,662 - $1.01 Million
22,025 Added 55.06%
62,030 $2.65 Million
Q3 2019

Nov 01, 2019
BUY
$42.5 - $63.11 $14,110 - $20,952
332 Added 0.84%
40,005 $1.71 Million
Q2 2019

Aug 09, 2019
BUY
$54.93 - $74.36 $377,424 - $510,927
6,871 Added 20.95%
39,673 $2.52 Million
Q1 2019

May 13, 2019
BUY
$39.87 - $69.36 $218,288 - $379,746
5,475 Added 20.04%
32,802 $2.28 Million
Q4 2018

Feb 11, 2019
SELL
$38.89 - $77.3 $1.77 Million - $3.52 Million
-45,486 Reduced 62.47%
27,327 $1.19 Million
Q3 2018

Oct 26, 2018
BUY
$71.81 - $90.15 $3.24 Million - $4.07 Million
45,097 Added 162.71%
72,813 $5.57 Million
Q2 2018

Aug 08, 2018
SELL
$48.54 - $85.31 $27,959 - $49,138
-576 Reduced 2.04%
27,716 $2.13 Million
Q1 2018

May 11, 2018
BUY
$44.33 - $58.52 $140,526 - $185,508
3,170 Added 12.62%
28,292 $1.44 Million
Q4 2017

Feb 06, 2018
SELL
$43.54 - $57.32 $653,012 - $859,685
-14,998 Reduced 37.38%
25,122 $1.18 Million
Q3 2017

Nov 07, 2017
BUY
$49.79 - $66.32 $2 Million - $2.66 Million
40,120
40,120 $2.14 Million

Others Institutions Holding RARE

# of Institutions
325
Shares Held
85.6M
Call Options Held
520K
Put Options Held
406K
View Full List

About Ultragenyx Pharmaceutical Inc.

RARE Quotes by TradingView
  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.07B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email